GEN-MKT-18-7897-A
Aug 26, 2016 | Blogs, Life Science Research, Proteomics | 0 comments
Here is the latest update on the Worldwide Efforts to Accelerate Precision Medicine
The NIH recently issued a press release in early July announcing $55 million in awards. According to the release, the $55 million award in the fiscal year 2016 will go towards building the foundational partnerships and infrastructure needed to launch the Cohort Program of President Obama’s Precision Medicine Initiative (PMI). The PMI Cohort Program is a landmark longitudinal research effort that aims to engage 1 million or more U.S. participants to improve the ability to prevent and treat disease based on individual differences in lifestyle, environment, and genetics.
The press release goes on the state that the PMI Cohort Program is one of the most ambitious research projects in history and will set the foundation for new ways of engaging people in research. PMI volunteers will be asked to contribute a wide range of health, environment and lifestyle information. They will also be invited to answer questions about their health history and status, share their genomic and other biological information through simple blood and urine tests and grant access to their clinical data from electronic health records. Also, mobile health devices and apps will provide lifestyle data and environmental exposures in real time. All of this will be accomplished with essential privacy and security safeguards. As partners in the research, participants will have ongoing input into study design and implementation, as well as access to a wide range of their individual and aggregated study results.
The SCIEX SolutionAs the promise of precision medicine continues to evolve; researchers will need powerful tools and application support to perform the Omics research at an industrialized scale that is sufficient to build the scientific foundation of precision medicine.
SCIEX has been focused on industrializing the proteomics solutions to enable large-scale proteome studies to advance research. Centered around the microflow SWATH® acquisition strategy for collecting digital proteome maps, data processing has been moved to the cloud with the OneOmics™ project to provide the compute power for processing these maps. Protocols also have been automated to provide the reproducibility required, again at an appropriate scale to feed the pipeline.
The same principles have been applied to industrializing quantitative lipidomics, with the launch of the Lipidyzer™ Platform.With SCIEX technologies, you can accelerate the pace of your research to identify key genes, proteins, lipids and metabolites in complex systems biology and then integrate your findings to gain a comprehensive insight to further understand health and disease.Want to know more about available methods? Comment below!
References
The Echo® MS+ system is a novel platform for Acoustic Ejection Mass Spectrometry (AEMS) and combines the speed of acoustic sampling with the selectivity of mass spectrometry. This platform has been designed for high throughput analysis of small and large molecules. The technology combines Acoustic Droplet Ejection (ADE), an Open Port Interface (OPI) and could be coupled with the SCIEX Triple Quad 6500+ system or the ZenoTOF 7600 system.
The Echo® MS+ system comprises of an open-port interface (OPI) and acoustic droplet ejection (ADE) module which could be coupled with a mass spectrometer. The mass spectrometer could either be a SCIEX Triple Quad 6500+ system or the ZenoTOF 7600 system. This non-liquid chromatography based; high-throughput screening platform enables rapid analysis of compounds at speeds of up to 1 sample/second.
The ability to consistently achieve reproducible results on many complex samples across multiple days is critical to a routine clinical laboratory. Laboratories relying on analytical instrumentation require stability and robustness to perform a variety of screening and confirmatory assays with confidence. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) has become the preferred analytical method in the clinical laboratory to reliably perform clinical testing as it provides best-in-class performance and reliability for the most challenging assays. LC-MS/MS offers the required levels of sensitivity and specificity for the detection and quantitation of molecules from complex biological samples, helping laboratories deliver highly accurate data for a variety of clinically relevant analytes across a wide range of assays.
Posted by
You must be logged in to post a comment.
Share this post with your network